DOCSLIB.ORG

Genomic Inform™ Test Carrier Screening Gene List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genomic Inform™ Test Carrier Screening Gene List Genomic Inform™ Test Carrier screening gene list Genomic Inform™ provides comprehensive testing of more than 300 autosomal recessive and X-linked conditions, including all American College of Medical Genetics and Genomics (ACMG), American College of Obstetricians and Gynecologists (ACOG) and Jewish Genetic Disease Consortium recommended disorders. Autosomal recessive DISORDER GENE DISORDER GENE 11-beta-hydroxylase-deficient congenital CYP11B1 Amish infantile epilepsy syndrome ST3GAL5 adrenal hyperplasia Andermann syndrome SLC12A6 17-alpha-hydroxylase-deficient congenital CYP17A1 Arginase deficiency ARG1 adrenal hyperplasia Argininosuccinic aciduria ASL 17-beta-hydroxysteroid dehydrogenase HSD17B3 deficiency, type III Aromatase deficiency CYP19A1 2-Methylbutyryl-CoA dehydrogenase ACADSB Arthrogryposis, mental retardation, and SLC35A3 deficiency seizures§ 3-beta-hydroxysteroid dehydrogenase HSD3B2 Asparagine synthetase deficiency§ ASNS type II deficiency (Congenital adrenal hyperplasia) Aspartylglucosaminuria AGA 3-hydroxy-3-methylglutarayl-CoA (HMG- HMGCL Ataxia with vitamin E deficiency TTPA CoA) lyase deficiency Ataxia-telangiectasia§ ATM 3-hydroxyacyl-CoA dehydrogenase HADH Ataxia-telangiectasia-like disorder 1 MRE11A deficiency Atypical Gaucher disease PSAP 3-methylcrotonyl-CoA carboxylase MCC1, MCC2 deficiency Atypical Krabbe disease PSAP 3-methylglutaconic aciduria OPA3 Autoimmune polyendocrinopathy with AIRE type III (Costeff optic atrophy)§ candidiasis and ectodermal dysplasia§ 6-pyruvoyl-tetrahydropterin synthase PTS Autosomal recessive deafness 77§ LOXHD1 deficiency Autosomal recessive spastic ataxia of SACS Abetalipoproteinemia§ MTTP Charlevoix-Saguenay (ARSACS) ACAD9 deficiency ACAD9 Bardet-Biedl syndrome§ ARL6, BBS1, BBS2, BBS4, BBS5, BBS7, BBS9, BBS10, BBS12, MKKS, MKS1, Achalasia-addisonianism-alacrima AAAS TTC8 syndrome Bare lymphocyte syndrome type II CIITA Achromatopsia ATF6, CNGA3, CNGB3, GNAT2, PDE6C Bartter syndrome type I SLC12A1 Acrodermatitis enteropathica SLC39A4 Bartter syndrome type II KCNJ1 Acute infantile liver failure§ TRMU Bartter syndrome type III CLCNKB Adenosine deaminase 2 deficiency ADA2 Bartter syndrome type IV BSND, CLCNKA, CLCNKB Adenosine deaminase deficiency ADA BCS1L-related disorders (Mitochondrial BCS1L Adult polyglucosan body disease GBE1 complex IIIdeficiency, Bjornstad syndrome, Aicardi-Goutieres syndrome ADAR, RNASEH2A, RNASEH2B, Leigh syndrome) RNASEH2C, SAMHD1, TREX1 Bernard-Soulier syndrome type A1 GP1BA Alexander disease GFAP Bernard-Soulier syndrome type B1 GP1BB Alkaptonuria HGD Bernard-Soulier syndrome type C GP9 Alpha-1 antitrypsin deficiency SERPINA1 Beta-globin-related hemoglobinopathies†‡§ HBB Alpha-mannosidosis MAN2B1 (Beta-thalassemia, Sickle cell disease) Alpha-thalassemia†‡§ HBA1/HBA2 Beta-ketothiolase deficiency ACAT1 Alport Syndrome§ COL4A3, COL4A4 Beta-mannosidosis MANBA Alström syndrome ALMS1 Bilateral frontoparietal polymicrogyria ADGRG1 DISORDER GENE DISORDER GENE Biotinidase deficiency BTD Early onset myopathy with fatal TTN cardiomyopathy (Salih myopathy) Bloom syndrome†‡§ BLM Ehlers-Danlos syndrome§ ADAMTS2, FKBP14, PLOD1, TNXB Canavan disease†‡§ ASPA Ellis-van Creveld syndrome EVC, EVC2 Carbamoylphosphate synthetase I defi- CPS1 ciency Enhanced S-cone syndrome§ NR2E3 Carnitine palmitoyltransferase I deficiency CPT1A Epiphyseal dysplasia, multiple, 7 CANT1 Carnitine palmitoyltransferase II defi- CPT2 Ethylmalonic encephalopathy ETHE1 ciency§ Factor V deficiency F5 Carpenter syndrome RAB23 Factor XI deficiency§ F11 Cartilage-hair hypoplasia-anauxetic dys- RMRP Familial dysautonomia†‡§ IKBKAP plasia spectrum disorders Familial hypercholesterolemia§ LDLR, LDLRAP1 Cerebral creatine deficiency syndrome 1 SLC6A8 Familial hyperinsulinemic hypoglycemia HADH, KCNJ11 Cerebrotendinous xanthomatosis§ CYP27A1 Familial hyperinsulinism‡§ ABCC8, KCNJ11 Charcot-Marie-Tooth disease NDRG1 Familial mediterranean fever§ MEFV Chediak-Higashi syndrome LYST Fanconi anemia†‡§ FANCA, FANCC, FANCD2, FANCE, Chorea-acanthocytosis§ VPS13A FANCF, FANCG, FANCI, FANCL, FANCM Choroidal dystrophy, central areolar 1 GUCY2D Fetal akinesia deformation sequence DOK7 Choroideremia CHM Fumarate hydratase deficiency FH Chronic granulomatous disease§ CYBA, NCF1, NCF2 Galactokinase deficiency galactosemia GALK1 Citrin deficiency SLC25A13 Galactosemia§ GALT Citrullinemia type 1 ASS1 Gaucher disease†‡§ GBA COACH syndrome RPGRIP1L Geroderma osteodysplastica GORAB Cockayne syndrome type A ERCC8 Gilbert syndrome UGT1A1 Cockayne syndrome type B ERCC6 Gitelman syndrome SLC12A3 Cohen syndrome VPS13B Glutaric acidemia type I GCDH Combined malonic and methylmalonic ACSF3 Glutaric acidemia type II ETFA, ETFB, ETFDH aciduria Glycine encephalopathy AMT, GLDC Combined oxidative phosphorylation GFM1, TSFM deficiency Glycogen storage disease IXb PHKB Combined pituitary hormone deficiency LHX3, PROP1 Glycogen storage disease IXc PHKG2 ‡§ Congenital adrenal hyperplasia due to CYP21A2 Glycogen storage disease type Ia G6PC 21-alpha-hydroxylase deficiency Glycogen storage disease type Ib SLC37A4 Congenital amegakaryocytic MPL Glycogen storage disease type II GAA § thrombocytopenia (Pompe disease)§ § Congenital disorder of glycosylation ALG6, MPI, PMM2 Glycogen storage disease type IV§ GBE1 Congenital Finnish nephrosis NPHS1 Glycogen storage disease type V PYGM Congenital insensitivity to pain with NTRK1 Glycogen storage disease type III AGL anhidrosis§ Glycogen storage disease type VII§ PFKM Congenital myasthenic syndrome§ CHAT, CHRNE, COLQ, DOK7, GFPT1, RAPSN Glycogen storage disease VI PYGL Congenital neutropenia HAX1, VPS45 GRACILE syndrome BCS1L Corneal dystrophy and perceptive deafness SLC4A11 Guanidinoacetate methyltransferase GAMT deficiency (Cerebral creatine deficiency § Corticosterone methyloxidase deficiency CYP11B2 syndrome 2) Crigler-Najjar syndrome UGT1A1 Hemochromatosis type 1 HFE †‡§ Cystic fibrosis CFTR Hemochromatosis type 2A HFE2 Cystinosis CTNS Hemochromatosis type 3 TFR2 D-bifunctional protein deficiency HSD17B4 Hereditary fructose intolerance ALDOB Desbuquois dysplasia type I CANT1 Hermansky-Pudlak syndrome§ AP3B1, HPS1, HPS3, HPS4, HPS5, DHDDS-related disorders (including DHDDS HPS6 Congenital disorder of glycoslylation) Holocarboxylase synthetase deficiency HLCS Dihydropyrimidine dehydrogenase DPYD, DLD Homocystinuria§ CBS, MTHFR, MTRR deficiency§ Hydrolethalus syndrome type 1 HYLS1 DMD-related dystrophinopathy (Duchenne DMD / Becker muscular dystrophy, Dilated Hyperornithinemia-hyperammonemia- SLC25A15 cardiomyopathy) homocitrullinuria (HHH) syndrome Dysferlinopathy DYSF Hyperphospatemic tumoral calcinosis, GALNT3 familial Dyskeratosis congenita RTEL1, TERT Hypohidrotic ectodermal dysplasia EDA, EDAR Dystrophic epidermolysis bullosa COL7A1 DISORDER GENE DISORDER GENE Hypophosphatasia ALPL Mitochondrial myopathy and sideroblastic PUS1 anemia§ Hypoprothrombinemia F2 Mitochondrial recessive ataxia syndrome POLG Inclusion body myopathy 2§ GNE Mucolipidosis type II/III GNPTAB Infantile cerebral and cerebellar atrophy§ MED17 Mucolipidosis type IV†‡§ MCOLN1 Isovaleric acidemia IVD Mucolipidosis type III GNPTG Johanson-Blizzard syndrome UBR1 Mucopolysaccharidosis type I (includes IDUA Joubert syndrome‡§ AHI1, CEP290, CC2D2A, CPLANE1, Hurler, Hurler-Scheie, and Scheie CSPP1, INPP5E, KIAA0586, MKS1, syndromes) RPGRIP1L, TMEM67, TMEM216, TMEM231 Mucopolysaccharidosis type IX HYAL1 Junctional epidermolysis bullosa LAMA3, LAMB3, LAMC2 Mucopolysaccharidosis type VI ARSB (Maroteaux-Lamy syndrome) Krabbe disease GALC Mucopolysaccharidosis type IIIA SGSH Kufor-Rakeb syndrome ATP13A2 (Sanfilippo A syndrome) LAMA2-related muscular dystrophy LAMA2 Mucopolysaccharidosis type IIIB NAGLU Lamellar ichthyosis type 1 TGM1 Mucopolysaccharidosis type IIIC HGSNAT Leber congenital amaurosis§ CEP290, CRB1, GUCY2D, LCA5, RDH12, (Sanfilippo syndrome) RPE65 Mucopolysaccharidosis type IIID GNS Leigh syndrome, French Canadian type LRPPRC (Sanfilippo syndrome) Lethal arthrogryposis with anterior horn GLE1 Mucopolysaccharidosis type IVB (Morquio GLB1 cell disease B syndrome) / GM1 gangliosidosis Lethal congenital contracture syndrome 1 GLE1 Mulibrey nanism TRIM37 Leukoencephalopathy with vanishing EIF2B5 Multiple sulfatase deficiency§ SUMF1 white matter Muscle-Eye-Brain disease and other POMGNT1 Leydig cell hypoplasia LHCGR POMGNT1-related congenital muscular dystrophy-dystroglycanopathies Limb-girdle muscular dystrophy CAPN3, DYSF, POMT1, POMT2, SGCA, SGCB, SGCG, TTN Muscular dystrophy-dystroglycanopathy LARGE1, POMT1, POMT2 (congenital with brain and eye anomalies) Lipoid congenital adrenal hyperplasia STAR Muscular dystrophy-dystroglycanopathy LARGE1, MKKS, POMT1, POMT2 Lipoprotein lipase deficiency LPL (congenital with mental retardation) Long chain 3-hydroxyacyl-CoA HADHA Muscular dystrophy-dystroglycanopathy LHCGR dehydrogenase (LCHAD) deficiency (congenital with mental retardation) type Lysinuric protein intolerance SLC7A7 6B § Lysosomal acid lipase deficiency§ (includes LIPA Myoneurogastrointestinal encephalopathy TYMP Wolman disease and Cholesterol ester N-Acetylglutamate synthase deficiency NAGS storage disease) Nemaline myopathy 2 NEB Major histocompatibility complex class II CIITA deficiency Nephrogenic diabetes insipidus AQP2 Maple syrup urine disease‡§ BCKDHA, BCKHB, DBT Neu-Laxova syndrome PHGDH Meckel syndrome CC2D2A, MKS1, RPGRIP1L, TMEM67, Neuronal ceroid lipofuscinosis CLN3, CLN5, CLN6, CLN8, CTSD, CTSF, TMEM216 DNAJC5, GRN. KCTD7, MFSD8, PPT1, TTP1 Medium chain acyl-CoA dehydrogenase ACADM (MCAD) deficiency
Load more

Recommended publications
  • Supplementary Materials
    DEPs in osteosarcoma cells comparing to osteoblastic cells Biological Process Protein Percentage of Hits metabolic process (GO:0008152) 29.3 29.3% cellular process (GO:0009987) 20.2 20.2% localization (GO:0051179) 9.4 9.4% biological regulation (GO:0065007) 8 8.0% developmental process (GO:0032502) 7.8 7.8% response to stimulus (GO:0050896) 5.6 5.6% cellular component organization (GO:0071840) 5.6 5.6% multicellular organismal process (GO:0032501) 4.4 4.4% immune system process (GO:0002376) 4.2 4.2% biological adhesion (GO:0022610) 2.7 2.7% apoptotic process (GO:0006915) 1.6 1.6% reproduction (GO:0000003) 0.8 0.8% locomotion (GO:0040011) 0.4 0.4% cell killing (GO:0001906) 0.1 0.1% 100.1% Genes 2179Hits 3870 biological adhesion apoptotic process … reproduction (GO:0000003) , 0.8% (GO:0022610) , 2.7% locomotion (GO:0040011) ,… immune system process cell killing (GO:0001906) , 0.1% (GO:0002376) , 4.2% multicellular organismal process (GO:0032501) , metabolic process 4.4% (GO:0008152) , 29.3% cellular component organization (GO:0071840) , 5.6% response to stimulus (GO:0050896), 5.6% developmental process (GO:0032502) , 7.8% biological regulation (GO:0065007) , 8.0% cellular process (GO:0009987) , 20.2% localization (GO:0051179) , 9.
    [Show full text]
  • Leading Article the Molecular and Genetic Base of Congenital Transport
    Gut 2000;46:585–587 585 Gut: first published as 10.1136/gut.46.5.585 on 1 May 2000. Downloaded from Leading article The molecular and genetic base of congenital transport defects In the past 10 years, several monogenetic abnormalities Given the size of SGLT1 mRNA (2.3 kb), the gene is large, have been identified in families with congenital intestinal with 15 exons, and the introns range between 3 and 2.2 kb. transport defects. Wright and colleagues12 described the A single base change was identified in the entire coding first, which concerns congenital glucose and galactose region of one child, a finding that was confirmed in the malabsorption. Subsequently, altered genes were identified other aZicted sister. This was a homozygous guanine to in partial or total loss of nutrient absorption, including adenine base change at position 92. The patient’s parents cystinuria, lysinuric protein intolerance, Menkes’ disease were heterozygotes for this mutation. In addition, it was (copper malabsorption), bile salt malabsorption, certain found that the 92 mutation was associated with inhibition forms of lipid malabsorption, and congenital chloride diar- of sugar transport by the protein. Since the first familial rhoea. Altered genes may also result in decreased secretion study, genomic DNA has been screened in 31 symptomatic (for chloride in cystic fibrosis) or increased absorption (for GGM patients in 27 kindred from diVerent parts of the sodium in Liddle’s syndrome or copper in Wilson’s world. In all 33 cases the mutation produced truncated or disease)—for general review see Scriver and colleagues,3 mutant proteins.
    [Show full text]
  • The National Economic Burden of Rare Disease Study February 2021
    Acknowledgements This study was sponsored by the EveryLife Foundation for Rare Diseases and made possible through the collaborative efforts of the national rare disease community and key stakeholders. The EveryLife Foundation thanks all those who shared their expertise and insights to provide invaluable input to the study including: the Lewin Group, the EveryLife Community Congress membership, the Technical Advisory Group for this study, leadership from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), the Undiagnosed Diseases Network (UDN), the Little Hercules Foundation, the Rare Disease Legislative Advocates (RDLA) Advisory Committee, SmithSolve, and our study funders. Most especially, we thank the members of our rare disease patient and caregiver community who participated in this effort and have helped to transform their lived experience into quantifiable data. LEWIN GROUP PROJECT STAFF Grace Yang, MPA, MA, Vice President Inna Cintina, PhD, Senior Consultant Matt Zhou, BS, Research Consultant Daniel Emont, MPH, Research Consultant Janice Lin, BS, Consultant Samuel Kallman, BA, BS, Research Consultant EVERYLIFE FOUNDATION PROJECT STAFF Annie Kennedy, BS, Chief of Policy and Advocacy Julia Jenkins, BA, Executive Director Jamie Sullivan, MPH, Director of Policy TECHNICAL ADVISORY GROUP Annie Kennedy, BS, Chief of Policy & Advocacy, EveryLife Foundation for Rare Diseases Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health Elisabeth M. Oehrlein, PhD, MS, Senior Director, Research and Programs, National Health Council Christina Hartman, Senior Director of Advocacy, The Assistance Fund Kathleen Stratton, National Academies of Science, Engineering and Medicine (NASEM) Steve Silvestri, Director, Government Affairs, Neurocrine Biosciences Inc.
    [Show full text]
  • Supplement 1 Overview of Dystonia Genes
    Supplement 1 Overview of genes that may cause dystonia in children and adolescents Gene (OMIM) Disease name/phenotype Mode of inheritance 1: (Formerly called) Primary dystonias (DYTs): TOR1A (605204) DYT1: Early-onset generalized AD primary torsion dystonia (PTD) TUBB4A (602662) DYT4: Whispering dystonia AD GCH1 (600225) DYT5: GTP-cyclohydrolase 1 AD deficiency THAP1 (609520) DYT6: Adolescent onset torsion AD dystonia, mixed type PNKD/MR1 (609023) DYT8: Paroxysmal non- AD kinesigenic dyskinesia SLC2A1 (138140) DYT9/18: Paroxysmal choreoathetosis with episodic AD ataxia and spasticity/GLUT1 deficiency syndrome-1 PRRT2 (614386) DYT10: Paroxysmal kinesigenic AD dyskinesia SGCE (604149) DYT11: Myoclonus-dystonia AD ATP1A3 (182350) DYT12: Rapid-onset dystonia AD parkinsonism PRKRA (603424) DYT16: Young-onset dystonia AR parkinsonism ANO3 (610110) DYT24: Primary focal dystonia AD GNAL (139312) DYT25: Primary torsion dystonia AD 2: Inborn errors of metabolism: GCDH (608801) Glutaric aciduria type 1 AR PCCA (232000) Propionic aciduria AR PCCB (232050) Propionic aciduria AR MUT (609058) Methylmalonic aciduria AR MMAA (607481) Cobalamin A deficiency AR MMAB (607568) Cobalamin B deficiency AR MMACHC (609831) Cobalamin C deficiency AR C2orf25 (611935) Cobalamin D deficiency AR MTRR (602568) Cobalamin E deficiency AR LMBRD1 (612625) Cobalamin F deficiency AR MTR (156570) Cobalamin G deficiency AR CBS (613381) Homocysteinuria AR PCBD (126090) Hyperphelaninemia variant D AR TH (191290) Tyrosine hydroxylase deficiency AR SPR (182125) Sepiaterine reductase
    [Show full text]
  • Open Full Page
    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders Michael F. Walsh1, Vivian Y. Chang2, Wendy K. Kohlmann3, Hamish S. Scott4, Christopher Cunniff5, Franck Bourdeaut6, Jan J. Molenaar7, Christopher C. Porter8, John T. Sandlund9, Sharon E. Plon10, Lisa L. Wang10, and Sharon A. Savage11 Abstract DNA repair syndromes are heterogeneous disorders caused by around the world to discuss and develop cancer surveillance pathogenic variants in genes encoding proteins key in DNA guidelines for children with cancer-prone disorders. Herein, replication and/or the cellular response to DNA damage. The we focus on the more common of the rare DNA repair dis- majority of these syndromes are inherited in an autosomal- orders: ataxia telangiectasia, Bloom syndrome, Fanconi ane- recessive manner, but autosomal-dominant and X-linked reces- mia, dyskeratosis congenita, Nijmegen breakage syndrome, sive disorders also exist. The clinical features of patients with DNA Rothmund–Thomson syndrome, and Xeroderma pigmento- repair syndromes are highly varied and dependent on the under- sum. Dedicated syndrome registries and a combination of lying genetic cause. Notably, all patients have elevated risks of basic science and clinical research have led to important in- syndrome-associated cancers, and many of these cancers present sights into the underlying biology of these disorders. Given the in childhood. Although it is clear that the risk of cancer is rarity of these disorders, it is recommended that centralized increased, there are limited data defining the true incidence of centers of excellence be involved directly or through consulta- cancer and almost no evidence-based approaches to cancer tion in caring for patients with heritable DNA repair syn- surveillance in patients with DNA repair disorders.
    [Show full text]
  • DISSERTATION PROTEOMIC PROFILING of the RAT RENAL PROXIMAL CONVOLUTED TUBULE in RESPONSE to CHRONIC METABOLIC ACIDOSIS Submitted
    DISSERTATION PROTEOMIC PROFILING OF THE RAT RENAL PROXIMAL CONVOLUTED TUBULE IN RESPONSE TO CHRONIC METABOLIC ACIDOSIS Submitted by Dana Marie Freund Department of Biochemistry and Molecular Biology In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Spring 2013 Doctoral Committee: Advisor: Norman Curthoys Co-Advisor: Jessica Prenni Jennifer Nyborg Olve Peersen Karen Dobos ABSTRACT PROTEOMIC PROFILING OF THE RAT RENAL PROXIMAL CONVOLUTED TUBULE IN RESPONSE TO CHRONIC METABOLIC ACIDOSIS The human kidneys contain more than one million glomeruli which filter nearly 200 liters of plasma per day. The proximal tubule is the segment of the nephron that immediately follows the glomeruli. This portion of the nephron contributes to fluid, electrolyte and nutrient homeostasis by reabsorbing 60-70% of the filtered water and NaCl and an even greater proportion of NaHCO3. The initial or convoluted portion of the proximal tubule reabsorbs nearly all of the nutrients in the glomerular filtrate and is the site of active secretion and many of the metabolic functions of the kidney. For example, the proximal convoluted tubule is the primary site of renal ammoniagenesis and gluconeogenesis, processes that are significantly activated during metabolic acidosis. Metabolic acidosis is a common clinical condition that is characterized by a decrease in blood pH and bicarbonate concentration. Metabolic acidosis also occurs frequently as a secondary complication, which adversely affects the outcome of patients with various life- threatening conditions. This type of acidosis can occur acutely, lasting for a few hours to a day, or as a chronic condition where acid-base balance is not fully restored.
    [Show full text]
  • CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions Christopher C
    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions Christopher C. Porter1, Todd E. Druley2, Ayelet Erez3, Roland P. Kuiper4, Kenan Onel5, Joshua D. Schiffman6, Kami Wolfe Schneider7, Sarah R. Scollon8, Hamish S. Scott9, Louise C. Strong10, Michael F. Walsh11, and Kim E. Nichols12 Abstract Leukemia, the most common childhood cancer, has long been patients. The panel recognized that for several conditions, recognized to occasionally run in families. The first clues about routine monitoring with complete blood counts and bone the genetic mechanisms underlying familial leukemia emerged marrow evaluations is essential to identify disease evolution in 1990 when Li-Fraumeni syndrome was linked to TP53 muta- and enable early intervention with allogeneic hematopoietic tions. Since this discovery, many other genes associated with stem cell transplantation. However, for others, less intensive hereditary predisposition to leukemia have been identified. surveillance may be considered. Because few reports describ- Although several of these disorders also predispose individuals ing the efficacy of surveillance exist, the recommendations to solid tumors, certain conditions exist in which individuals are derived by this panel are based on opinion, and local expe- specifically at increased risk to develop myelodysplastic syn- rience and will need to be revised over time. The development drome (MDS) and/or acute leukemia. The increasing identifica- of registries and clinical trials is urgently needed to enhance tion of affected individuals and families has raised questions understanding of the natural history of the leukemia-predis- around the efficacy, timing, and optimal methods of surveil- posing conditions, such that these surveillance recommenda- lance.
    [Show full text]
  • Phenotype Heterogeneity of Congenital Adrenal Hyperplasia Due
    Kor et al. BMC Medical Genetics (2018) 19:115 https://doi.org/10.1186/s12881-018-0629-2 CASE REPORT Open Access Phenotype heterogeneity of congenital adrenal hyperplasia due to genetic mosaicism and concomitant nephrogenic diabetes insipidus in a sibling Yılmaz Kor1†, Minjing Zou2†, Roua A. Al-Rijjal2, Dorota Monies2, Brian F. Meyer2 and Yufei Shi2* Abstract Background: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is an autosomal recessive disorder caused by mutations in the CYP21A2. Congenital nephrogenic diabetes insipidus (NDI) is a rare X- linked recessive or autosomal recessive disorder caused by mutations in either AVPR2 or AQP2. Genotype-phenotype discordance caused by genetic mosaicism in CAH patients has not been reported, nor the concomitant CAH and NDI. Case presentation: We investigated a patient with concomitant CAH and NDI from a consanguineous family. She (S- 1) presented with clitoromegaly at 3 month of age, and polydipsia and polyuria at 13 month of age. Her parents and two elder sisters (S-2 and S-3) were clinically normal, but elevated levels of serum 17-hydroxyprogesterone (17-OHP) were observed in the mother and S-2. The coding region of CYP21A2 and AQP2 were analyzed by PCR-sequencing analysis to identify genetic defects. Two homozygous CYP21A2 mutations (p.R357W and p.P454S) were identified in the proband and her mother and S-2. The apparent genotype-phenotype discordance was due to presence of small amount of wild-type CYP21A2 alleles in S-1, S-2, and their mother’s genome, thus protecting them from development of classic form of 21OHD (C21OHD).
    [Show full text]
  • Hereditary Galactokinase Deficiency J
    Arch Dis Child: first published as 10.1136/adc.46.248.465 on 1 August 1971. Downloaded from Alrchives of Disease in Childhood, 1971, 46, 465. Hereditary Galactokinase Deficiency J. G. H. COOK, N. A. DON, and TREVOR P. MANN From the Royal Alexandra Hospital for Sick Children, Brighton, Sussex Cook, J. G. H., Don, N. A., and Mann, T. P. (1971). Archives of Disease in Childhood, 46, 465. Hereditary galactokinase deficiency. A baby with galactokinase deficiency, a recessive inborn error of galactose metabolism, is des- cribed. The case is exceptional in that there was no evidence of gypsy blood in the family concerned. The investigation of neonatal hyperbilirubinaemia led to the discovery of galactosuria. As noted by others, the paucity of presenting features makes early diagnosis difficult, and detection by biochemical screening seems desirable. Cataract formation, of early onset, appears to be the only severe persisting complication and may be due to the biosynthesis and accumulation of galactitol in the lens. Ophthalmic surgeons need to be aware of this enzyme defect, because with early diagnosis and dietary treatment these lens changes should be reversible. Galactokinase catalyses the conversion of galac- and galactose diabetes had been made in this tose to galactose-l-phosphate, the first of three patient (Fanconi, 1933). In adulthood he was steps in the pathway by which galactose is converted found to have glycosuria as well as galactosuria, and copyright. to glucose (Fig.). an unexpectedly high level of urinary galactitol was detected. He was of average intelligence, and his handicaps, apart from poor vision, appeared to be (1) Galactose Gackinase Galactose-I-phosphate due to neurofibromatosis.
    [Show full text]
  • The Counsyl Foresight™ Carrier Screen
    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Disease Reference Book
    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
    [Show full text]